title: Human tissue kallikrein attenuates hypertension and secretes into circulation and urine after intramuscular gene delivery in hypertensive rats.
abstract: Systemic delivery of the human tissue kallikrein transgene has been shown to markedly delay the increase of blood pressure in hypertensive rat models. To demonstrate potential hypotensive effects of kallikrein via local delivery, adenovirus carrying the human tissue kallikrein gene was inoculated into quadriceps of spontaneously hypertensive rats (SHR). A single intramuscular injection of the kallikrein gene caused a significant delay of blood pressure increase for 5 weeks. The expression of human tissue kallikrein and its mRNA was identified solely in injected muscle. Immunoreactive human tissue kallikrein was detected in the muscle as well as in the circulation and urine of adult and newborn rats. Urinary kinin and cGMP levels increased significantly in rats receiving kallikrein gene delivery as compared with rats receiving control virus containing the LacZ gene. The detection of human tissue kallikrein in rat urine after local gene delivery into the muscle provides direct evidence that circulatory kallikrein can be secreted into the urine. These findings indicated that a continuous supply of human tissue kallikrein in the circulation is sufficient to reduce blood pressure and kallikrein gene delivery via the intramuscular route may have significant implications in therapeutic applications.
authors.affiliation: Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston 29425, USA.
authors.forename: J J
authors.initials: JJ
authors.lastname: Zhang
authors.forename: C
authors.initials: C
authors.lastname: Wang
authors.forename: K F
authors.initials: KF
authors.lastname: Lin
authors.forename: L
authors.initials: L
authors.lastname: Chao
authors.forename: J
authors.initials: J
authors.lastname: Chao
mesh_terms: D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D000831:Animals, Newborn; D001794:Blood Pressure / Q000187:drug effects; D015152:Blotting, Northern; D006152:Cyclic GMP / Q000652:urine; D017931:DNA Primers / Q000737:chemistry; D015316:Genetic Therapy; D005822:Genetic Vectors; D006973:Hypertension / Q000378:metabolism / Q000517:prevention & control*; D007273:Injections, Intramuscular; D007705:Kinins / Q000652:urine; D007763:Lac Operon / Q000235:genetics; D008297:Male; D018482:Muscle, Skeletal / Q000378:metabolism; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D051381:Rats; D011918:Rats, Inbred SHR; D020133:Reverse Transcriptase Polymerase Chain Reaction; D020840:Tissue Kallikreins / Q000097:blood / Q000235:genetics / Q000627:therapeutic use* / Q000652:urine
chemical_list: D017931:DNA Primers; D007705:Kinins; D012333:RNA, Messenger; D020840:Tissue Kallikreins; D006152:Cyclic GMP